Daewoong Pharmaceutical has won the Canadian government’s Good Manufacturing Practices (GMP) certification for the plant it set up there to produce Nabota, its brand of botulinum toxin.
Botulinum toxin, commonly called botox, is a biological medicine used in cosmetic procedures, such as improvement of wrinkles.
Daewoong Pharmaceutical filed an application with the Canadian Federal Ministry of Health in July last year for a license to sell Nabota in Canada. The company was notified in November last year that the application had been received. Currently, a screening process on Nabota is underway.
The Canadian government’s GMP certification for Daewoon’s manufacturing facility is a step required for the approval of the medicine.
Daewoong Pharmaceutical expects it would receive the final approval within this year.